Stimwave gears up for U.S. expansion, aims to hire 75

purple illustration of nerves
Stimwave, which recently earned FDA clearance for its MRI-safe peripheral nerve stimulator, is planning to ramp up sales in the U.S.

Neuromodulation player Stimwave is looking to hire up to 75 new employees to support its expanded commercialization drive in the U.S. The push comes as demand grows for its spinal cord stimulation (SCS) system and peripheral nerve stimulator. 

Pompano Beach, Florida-based Stimwave recently scored FDA clearance for its tiny, MRI-safe StimQ Peripheral Nerve Stimulator, indicated for the treatment of chronic pain in the peripheral nerves, or the nerves that connect the brain and spinal cord to the rest of the body. The wireless device is delivered to the affected nerve via injection and treats pain by transmitting small electrical pulses through a set of electrodes. 

FDA-cleared in 2014, Stimwave's Freedom SCS system is implanted next to the spinal cord and treats chronic low back pain and leg pain. Like the StimQ device, it is placed via injection and provides pain relief by delivering electrical pulses to the targeted nerve. 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Neurostimulation is an attractive alternative to opioids for chronic pain treatment. Stimwave will boost its sales and clinical teams to expand its reach in the chronic pain market, as well as to gain greater coverage for physicians and patients "demanding more freedom in therapy options." 

“The Stimwave team is on a journey to innovate and engineer new technology that has never been done before, which is a leap forward for medical science. We are extremely grateful for the market acceptance of our innovations and pleased to grow our support infrastructure to support that demand effectively," said CEO Laura Tyler Perryman, in a statement.

Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

The FDA approved a new, tiny pacemaker from Medtronic that does not require the wiring of separate electrodes between the implant and the heart.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.